BICO Group AB Class B (SE:BICO)
:BICO
Want to see SE:BICO full AI Analyst Report?
BICO Stock Chart & Stats
kr18.16
-kr2.08(-4.75%)
At close: 4:00 PM EST
kr18.16
-kr2.08(-4.75%)
Day’s Range― - ―
52-Week Rangekr15.30 - kr42.46
Previous CloseN/A
Volume245.45K
Average Volume (3M)288.59K
Market Cap
kr1.42B
Enterprise Valuekr1.61B
Total Cash (Recent Filing)kr1.28B
Total Debt (Recent Filing)kr1.50B
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Apr 29, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding69,074,900
10 Day Avg. Volume264,488
30 Day Avg. Volume288,586
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.85
Price to Sales (P/S)0.99
P/FCF Ratio26.97
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.19
Revenue Forecast (FY)kr1.58B
Bulls Say, Bears Say
Bulls Say
Improving Cash GenerationSustained positive operating and free cash flow over recent years is a durable strength: it supports near-term liquidity, funds R&D and bolt‑on deals without immediate equity raises, and enables management to settle convertibles and reduce refinancing pressure. However, cash remains modest versus debt so execution must continue to build on this trend to materially improve financial flexibility.
Q4 Profitability RecoveryA clear Q4 margin and cashflow recovery indicates management's cost discipline and a new operational baseline. If Q4 margins reflect sustainable expense levels and improved project execution, the company can convert future revenue growth into durable profitability, reduce need for external funding, and improve investor confidence over the medium term.
Strategic Focus On Lab Automation And AI/softwareShifting to software/AI-heavy R&D and lab automation focuses the business on higher recurring revenue, platform differentiation and partner-driven commercial reach. Product launches and partnerships (e.g., GoSimple, Green Button Go collaborations) can expand sticky software revenue and improve gross margins over time if adoption by pharma and labs scales.
Bears Say
Multi-year Revenue ContractionThree consecutive years of declining revenue point to structural demand or portfolio competitiveness issues. Persistent top-line weakness erodes operating leverage, limits scale benefits for consumables and software upsell, and makes it harder to sustainably restore margins even if recent quarters show improvement.
Very Low Full‑year ProfitabilityNear‑zero adjusted EBITDA and compressed gross margins reflect deep profitability issues that reduce internal funding for growth initiatives. Sustained low margins increase the risk of further equity erosion, constrain R&D and commercial investments, and leave the company vulnerable to macro slowdowns and project execution setbacks.
Rising Leverage And Equity Erosion RiskIncreased leverage and shrinking equity reduce financial flexibility and raise interest and covenant risks, especially after issuing new bonds. While a pro forma cash buffer exists post-convertible settlement, the balance sheet remains vulnerable to further losses, limiting capacity for large M&A or cyclical absorption without new financing.
BICO Group AB Class B News
BICO FAQ
What was BICO Group AB Class B’s price range in the past 12 months?
BICO Group AB Class B lowest stock price was kr15.30 and its highest was kr42.46 in the past 12 months.
What is BICO Group AB Class B’s market cap?
BICO Group AB Class B’s market cap is kr1.42B.
When is BICO Group AB Class B’s upcoming earnings report date?
BICO Group AB Class B’s upcoming earnings report date is Apr 29, 2026 which is in 11 days.
How were BICO Group AB Class B’s earnings last quarter?
BICO Group AB Class B released its earnings results on Feb 18, 2026. The company reported -kr0.82 earnings per share for the quarter, missing the consensus estimate of -kr0.467 by -kr0.353.
Is BICO Group AB Class B overvalued?
According to Wall Street analysts BICO Group AB Class B’s price is currently Overvalued.
Does BICO Group AB Class B pay dividends?
BICO Group AB Class B does not currently pay dividends.
What is BICO Group AB Class B’s EPS estimate?
BICO Group AB Class B’s EPS estimate is -1.
How many shares outstanding does BICO Group AB Class B have?
BICO Group AB Class B has 69,074,900 shares outstanding.
What happened to BICO Group AB Class B’s price movement after its last earnings report?
BICO Group AB Class B reported an EPS of -kr0.82 in its last earnings report, missing expectations of -kr0.467. Following the earnings report the stock price went up 12.875%.
Which hedge fund is a major shareholder of BICO Group AB Class B?
Currently, no hedge funds are holding shares in SE:BICO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BICO Group AB Class B
BICO Group AB Class B (BICO) is a leading company in the biotechnology sector, focusing on innovative solutions in the life sciences and healthcare industries. The company specializes in biofabrication, offering advanced technologies and services for the development of tissue engineering and regenerative medicine. BICO's core products include bioprinters, biomaterials, and related software, which enable researchers and medical professionals to create and manipulate biological structures for research and therapeutic applications.
BICO Company Deck
BICO Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: the company executed its strategic repositioning (BICO 2.0), strengthened its cash position through a EUR 40m bond issuance, reduced debt and demonstrated a clear Q4 recovery with strong margins and Biosero momentum. However, full-year financials were weak (organic sales -8%, adjusted EBITDA only SEK 5m, Lab Automation full-year decline -26% and negative EBITDA), and the business faced notable macro headwinds (US academia funding cuts, FX pressure and cautious CapEx). Product launches, partnerships and AI-enabled offerings provide a foundation for growth, but near-term performance still reflects industry and legacy operational challenges.View all SE:BICO earnings summariesTechnical Analysis
CellaVision AB
―
Senzime AB
―
Bactiguard Holding AB
―
C-Rad AB Class B
―
Sedana Medical AB
―
Options Prices
Currently, No data available
---